Navigation Links
Sigma-Aldrich Announces the Integration of Riedel-De Haen Into Core Product Brands
Date:4/30/2008

Move Marks a New Step in the Company's Global Branding Strategy

ST. LOUIS, April 30 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today announced the full integration of its Riedel-de Haen(R) Laboratory Reagents into its core product brands effective May 1, 2008 (http://www.sigma-aldrich.com/rebranding).

"We have created a strong international presence with our products and services," said Josef Zihlmann, Global Vice President of Marketing and Sales for the Research Specialties and Research Essentials business units at Sigma-Aldrich. "We can best serve our customers with a streamlined product range under a reduced core group of brands with global recognition."

Zihlmann continued: "The Riedel-de Haen products will still be available to customers, and will be distributed through the Fluka brand. Both Fluka and Riedel-de Haen products share not only a European heritage, but are also recognized in the market for their high quality. We will also maintain trade names for product groups such as Hydranal(R) Karl Fischer Reagents (http://www.sigma-aldrich.com/hydranal). These products will appear with the Fluka logo on the label."

Serving the Company's research and laboratory customers, Sigma-Aldrich markets its products under the Sigma(R), Aldrich(R), Fluka(R) and Supelco(R) brands. These are now used for products in the fields of Life Science, Chemistry, Analytical Reagents and Chromatography. Many products for general use in all laboratories are distributed under the Sigma-Aldrich label.

Riedel-de Haen laboratory reagents have been part of the Sigma-Aldrich offering since being acquired in 1997. They are manufactured at a facility in Seelze, Germany, and other European locations.

"The former Riedel-de Haen-branded products will continue to be manufactured in our own production units in Seelze as well as purchased from qualified producers," said Dr. Hans-Joachim Merrem, site manager. "It is important that we maintain the high quality and reliable service that our customers have come to expect of us. We enjoy a strong reputation internationally, and we have invested in sophisticated production, quality management and distribution infrastructure at the Seelze site. Although we are changing the brand under which the products are marketed and distributed, we will continue to ensure that this reputation remains the same."

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning website at http://www.sigma-aldrich.com.

Cautionary Statement: This release contains forward-looking statements relating to strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Company's expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Company's operations and conditions in the markets the Company serves. The Company does not undertake any obligation to update these forward-looking statements.

Sigma, Aldrich, Fluka, Supelco, Sigma-Aldrich, Riedel-de Haen and Hydranal are trademarks of Sigma-Aldrich Biotechnology LP and Sigma-Aldrich Co.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. Sigma-Aldrich and Lab Manager Magazine Present Webinar On Laboratory Environmental, Health and Safety Compliance Strategies
3. Sigma-Aldrich Expansion in Republic of China to Support SAFC Growth
4. Sigma-Aldrich and Ingenuity Systems Announce Partnership to Create E-Commerce Search Solution Based on Biological Knowledge
5. Sigma-Aldrich to Present at the UBS 2007 Global Life Sciences Conference on September 25, 2007
6. Sigma-Aldrich Names Patrick Sullivan New VP of Research and Development for Research Biotech
7. Sigma-Aldrich and the Universite de Montreal Establish Collaboration for RNA Interference Studies
8. Sigma-Aldrich Corporations 3rd Quarter 2007 Earnings Conference Call
9. Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types
10. Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54.
11. Sigma-Aldrich and Oxford BioMedica Win Key Ruling in Open Biosystems Patent Infringement Dispute
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... Linda, Ca (PRWEB) , ... February 28, 2017 , ... ... molecular interactions. SPR is an optical phenomenon that is sensitive to changes in the ... resonance condition is affected by changes in refractive index occurring up to 300 nm ...
(Date:2/28/2017)... , Feb. 28, 2017  Phosphorus, a ... today the formation of the Phosphorus Scientific Advisory ... experts chosen to advise the company on the ... multi-site research initiatives. Please visit http://phosphorus.com/about-us/ ... initiatives. "We,ve gathered some of the ...
(Date:2/28/2017)... -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing ... diseases, asthma and allergic diseases and cancer, today ... full year ended December 31, 2016 and provided ... clinical highlights. "During 2016, we made ... starting five clinical trials across our XmAb portfolio.  ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... New York , February 7, 2017 ... as ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or ... management and electronic transaction processing services, is pleased to ... of the Company. Effective January 31, 2017, ... the Board of Directors, CEO and President.  An experienced ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, Inc. ... immuno-oncology company specializing in the development of innovative ... treatment of cancer and metastatic disease, announced today ... GMP manufacturing of a second clinical lot of ... folate receptor alpha. The manufactured vaccine product will ...
Breaking Biology News(10 mins):